Genmab AS (FRA:GE91) Other Cash Payments from Operating Activities


FRA:GE91 Genmab AS FRA:GE91
93 GF Score
Price €21.80
GF Value €29.03
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS Other Cash Payments from Operating Activities?

Other Cash Payments from Operating Activities only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:GE91
93GF Score
Genmab AS FRA:GE91
Other Cash Payments from Operating Activities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Genmab AS (FRA:GE91) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of €21.80 is trading 24.9% below its estimated GF Value™ of €29.03. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for FRA:GE91:

  • Other Cash Payments from Operating Activities:
  • GF Value™: €29.03 vs. price of €21.80 (24.9% below fair value)
  • GF Score™: 93/100 with 5 warning signs

No single metric tells the full story. See the FRA:GE91 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
93GF Score

Get the complete analysis for FRA:GE91

Other Cash Payments from Operating Activities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.80
Price
€29.03
GF Value